Payment overview · 2025
General Payments
$172.22
10 reported records · 8 companies
Healthcare provider profile · identity verified
Alicia Danielle Cleaver, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · ATHENS, TX · NPI 1730409939
Verified facts
What the public records show
CMS Open Payments records show Alicia Danielle Cleaver, D.O. received $172.22 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.50 | 22.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $30.89 | 17.9% | 2 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $23.70 | 13.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.30 | 11.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.94 | 9.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.40 | 8.9% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $14.95 | 8.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.54 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $172.22 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.50 | 2 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 185 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 160 | 41 |
| Gabapentin | Gabapentin | 146 | 34 |
| Losartan Potassium | Losartan Potassium | 142 | 31 |
| Lisinopril | Lisinopril | 141 | 32 |
| Omeprazole | Omeprazole | 111 | 21 |
| Trazodone Hcl | Trazodone Hcl | 102 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 22 |
| Meloxicam | Meloxicam | 93 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 19 |
| Metformin Hcl | Metformin Hcl | 89 | 23 |
| Simvastatin | Simvastatin | 83 | 24 |
| Tramadol Hcl | Tramadol Hcl | 80 | 16 |
| Glimepiride | Glimepiride | 76 | 18 |
| Montelukast Sodium | Montelukast Sodium | 75 | 16 |
| Alendronate Sodium | Alendronate Sodium | 64 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 13 |
| Pregabalin | Pregabalin | 64 | suppressed |
| Bupropion Xl | Bupropion Hcl | 63 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 12 |
| Furosemide | Furosemide | 58 | 15 |
| Potassium Chloride | Potassium Chloride | 56 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 19 |
| Carvedilol | Carvedilol | 51 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 50 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 11 |
| Famotidine | Famotidine | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Naproxen | Naproxen | 34 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Eliquis | Apixaban | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $172.22 · 10 records | Novo Nordisk Inc | AIRSUPRA, CARTO 3, Dexcom G6 Transmitter, ECC Solutions, ELIQUIS, General - Therapies, Kerendia, NURTEC ODT, WaveWriter Alpha Prime 16, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error